Dr Prabhakar Rajan

PhD, FRCS (Urol), FHEA
Clinical Senior Lecturer in Urology
Group Leader
Research Focus

My laboratory research explores alternative pre-mRNA splicing in prostate cancer (PCa) biology, and liquid biopsy-derived molecular biomarkers of treatment outcomes. My clinical research investigates chemo-preventative strategies to reduce low risk PCa progression, and surgical alternatives to cytotoxic chemotherapy for metastatic testicular cancer.

Key Publications

Identification of altered biological processes in heterogeneous RNA-sequencing data by discretization of expression profiles. Nucleic Acids Res (2020) 48(4):1730-1747. PMID: 31889184

Androgen Receptor Burden and Poor Response to Abiraterone or Enzalutamide in TP53 Wild-Type Metastatic Castration-Resistant Prostate Cancer. JAMA Oncol (2019) 5(7):1060-1062. PMID: 31046065

Oncologic Outcomes After Robot-assisted Radical Prostatectomy: A Large European Single-centre Cohort with Median 10-Year Follow-up. Eur Urol Focus (2018) 4(3):351-359. PMID: 28753802

Effect of Comorbidity on Prostate Cancer-Specific Mortality: A Prospective Observational Study. J Clin Oncol (2017) 35(31):3566-3574. PMID: 28930493

Next-generation sequencing of advanced prostate cancer treated with androgen-deprivation therapy. Eur Urol (2014) 66(1):32-9. PMID: 24054872

Major Funding
  • 2020-2021- CRUK Barts Centre Development Fund, Exploiting PTEN loss in Hypoxic Tumour Cells (Principal Investigator), £10,000

  • 2018-2021- QMUL Life Sciences Initiative PhD Studentship, Understanding alternative splicing in human cancer by proteomics informed by transcriptomics (PIT) (Co-applicant with Professor Conrad Bessant), ~£80,000

  • 2017-2021- The Urology Foundation/The John Black Charitable Foundation Project Grant, Androgen receptor splice variants in prostate cancer (Principal Investigator), £249,999

Other Activities
  • 2019 to date- Member: National Cancer Research Institute (NCRI) Teenage & Young Adults (TYA) and Germ Cell Tumours Clinical Studies Group (CSG) (Germ Cell Tumours Subgroup)
  • 2019 to date- Member: NCRI Prostate Cancer CSG (Advanced Disease Subgroup)
Research

My laboratory-based research programme explores a link between alternative pre-mRNA splicing (AS), a ubiquitous post-transcriptional gene regulatory mechanism, and prostate cancer (PCa) phenotypes.  During AS, coding (exons) and non-coding (introns) regions of a gene are shuffled to create protein isoforms with different functions.  AS is regulated by trans-acting RNA-binding proteins (RBPs), and tightly coupled to transcription. We are studying the link between dysregulation of transcriptional and intracellular signalling processes and AS, mediated by RBPs. 

Our translational research examines how blood-derived liquid biopsy molecular biomarkers can be used to improve treatment outcomes for PCa patients. With NHS colleagues, we are investigating minimally-invasive surgical alternatives to chemotherapy for metastatic testicular cancer to reduce the therapy burden and toxicity. In collaboration with the Wolfson Institute of Preventative Medicine, we are exploring how minimally-toxic chemo-preventative strategies may reduce PCa progression on active surveillance.

Other Activities
  • 2019 to date- Member: National Cancer Research Institute (NCRI) Teenage & Young Adults (TYA) and Germ Cell Tumours Clinical Studies Group (CSG) (Germ Cell Tumours Subgroup)
  • 2019 to date- Member: NCRI Prostate Cancer CSG (Advanced Disease Subgroup)
Major Funding
  • 2020-2021- CRUK Barts Centre Development Fund, Exploiting PTEN loss in Hypoxic Tumour Cells (Principal Investigator), £10,000

  • 2018-2021- QMUL Life Sciences Initiative PhD Studentship, Understanding alternative splicing in human cancer by proteomics informed by transcriptomics (PIT) (Co-applicant with Professor Conrad Bessant), ~£80,000

  • 2017-2021- The Urology Foundation/The John Black Charitable Foundation Project Grant, Androgen receptor splice variants in prostate cancer (Principal Investigator), £249,999
  • 2013-2019- Royal College of Surgeons of England/Cancer Research UK- Clinician Scientist Fellowship in Surgery, Analysis of alternative splicing in prostate cancer metastasis regulated by the RNA-binding proteins Sam68 and hnRNP A2/B1 (Principal Investigator), >£800,000
Recent Publications

Warning: simplexml_load_file(): /var/www/vhosts/bartscancer.london/httpdocs/pub-xml/37032.xml:2: parser error : Start tag expected, '<' not found in /var/www/vhosts/bartscancer.london/httpdocs/wp-content/themes/barts-cancer/functions/widgets.php on line 338

Warning: simplexml_load_file(): No output found matching request criteria! in /var/www/vhosts/bartscancer.london/httpdocs/wp-content/themes/barts-cancer/functions/widgets.php on line 338

Warning: simplexml_load_file(): ^ in /var/www/vhosts/bartscancer.london/httpdocs/wp-content/themes/barts-cancer/functions/widgets.php on line 338

Warning: Invalid argument supplied for foreach() in /var/www/vhosts/bartscancer.london/httpdocs/wp-content/themes/barts-cancer/functions/widgets.php on line 341
For additional publications, please click here
Team

Postdoctoral Researchers
Dr John Foster

PhD Student
Mr Esteban Gea (with Professor Conrad Bessant)

 

Biography

Key qualifications

  • 2008 PhD (Prostate Cancer Biology), Newcastle University
  • 2012 FRCS(Urol.), Royal College of Surgeons of England
  • 2017 FHEA, Higher Education Academy

Recent appointments

  • 2008-2014 West of Scotland Training Programme in Urology
  • 2008-2013 Clinical Lecturer in Urology, University of Glasgow
  • 2013-2015 Clinical Research Fellow, University of Glasgow
  • 2015-to date Consultant Urologist, Barts Health and University College London Hospitals NHS Trusts
  • 2015-to date Clinical Senior Lecturer in Urology, Queen Mary University of London
  • 2018 to date Turing Fellow, The Alan Turing Institute
Upcoming Events
  1. 2020 Circulating Cancer Biomarker Symposium

    May 4 @ 9:00 am - 5:30 pm
  2. The London Pancreas Workshop 2020

    September 11 @ 9:30 am - 4:30 pm
© 2013 ~ 2020 Cancer Research UK Barts Centre